My goodness 2da, we have 7 indies for this BIC drug in pona that are one or two clinical trials away from approval and you're assigning a $15 valuation and making it as Denner's exit point? I understand your frustration as well as the other longs who stayed around because I am one of you. We are one very very good news away from being a 20 bagger, like the new molecule targeting EGFR or KRAS
mutations(case in point CLVS), like the FDA announcing that Iclusig can proceed with testing for first line, like having a consensus from oncologists that 113 is BIC and better than the other two competition, like the FDA approving 113 much sooner like pona, like having a validated drug(s) partnership rumor with a BP, etc..jmo.
This is a no brainer.
